希瑪眼科(03309.HK)與諾華合作於珠海眼科醫院使用在港註冊藥物
希瑪眼科(03309.HK)公布,與諾華(中國)簽訂戰略合作備忘錄,雙方同意聯合支持「港澳藥械通」新政策,該政策允許在粵港澳大灣區內營運的指定醫療機構,使用已在香港註冊及使用,但未在內地註冊或使用的藥物及療器械。
諾華(中國)與集團擬根據措施使用的第一種藥物為Beovu,為新一代抗血管內皮生長因子藥物,該藥已於美國獲批用於治療濕性老年性黃變性,這是一種影響眼球正後方的視網膜中心的疾病。雙方戰略合作亦包括收集臨床資料,以供Beovu日後向國家藥品監督管理局進行正式註冊申請時使用。
集團表示,Beovu在過去幾個月在香港上市,已成功應用並取得良效,透過藥械通在集團珠海希瑪林順潮眼科醫院使用的每種藥物,皆會嚴格管理和為病人作用藥後追蹤,監管其藥效和安全性。集團預計,將有更多創新藥物及治療方法根據措施,在集團的珠海希瑪林順潮眼科醫院得以應用,包括但不限於人工角膜、人工虹膜及不含防腐劑的青光眼藥物。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.